Source comparison
AOD-9604 Dosage Comparison: Clinical Protocols vs Common Errors
300mcg daily (morning fasted) Subcutaneous, abdominal 8–12% body fat reduction over 12 weeks in controlled trials 5mg vial + 2mL bac water = 2.5mg/mL; draw 12 units (0.12mL) Drawing 10 units (250mcg actual dose) due to miscalculation Gold standard. Maximal lip
This comparison does not assign a generated winner or score.
- 300mcg daily (morning fasted)
- Subcutaneous, abdominal
- 8–12% body fat reduction over 12 weeks in controlled trials
- 5mg vial + 2mL bac water = 2.5mg/mL; draw 12 units (0.12mL)
- Drawing 10 units (250mcg actual dose) due to miscalculation
- Gold standard. Maximal lipolytic effect without dose-dependent sides
- 500mcg daily (evening fed)
- Subcutaneous, thigh
- Marginal improvement over 300mcg; no statistically significant difference in fat oxidation
- 5mg vial + 1mL bac water = 5mg/mL; draw 10 units (0.1mL)
- Injecting during fed state when insulin inhibits lipolysis
- Higher cost, no additional benefit; timing negates dose advantage
- 150mcg daily (titration start)
- Below receptor saturation threshold; used for tolerance assessment in week 1 only
- 5mg vial + 2mL bac water = 2.5mg/mL; draw 6 units (0.06mL)
- Remaining at 150mcg beyond week 1 due to fear of sides
- Appropriate for initial tolerance check; should escalate to 300mcg by day 8
- 1mg daily (high dose)
- Subcutaneous, varies
- No additional fat loss vs 300mcg; increased injection site reactions (redness, itching)
- 5mg vial + 1mL bac water = 5mg/mL; draw 20 units (0.2mL)
- Assuming more peptide = more results (dose-response plateau ignored)
- Wasteful. Lipolytic ceiling reached at 300–500mcg; excess peptide clears without effect